vimarsana.com

Latest Breaking News On - California eastern district - Page 1 : vimarsana.com

California ICE Detainees Hunger Strike Is Part Of A Long Fight For Freedom

At two Immigration and Customs Enforcement detention centers in California’s Central Valley, a cycle of resistance and retaliation has been intensifying

ICE detainees hunger strike in Central Valley, California

Individuals confined inside two detention centers are fighting for better wages and conditions while building momentum to secure their release and shut down the for-profit immigrant jails for good.

ANALYTICS: Environmental Matters Over the Last Two Years

Agriculture your username January 18, 2021 Environmental lawsuits, frequently spearheaded by advocacy organizations trying to protect the enjoyment of wildlife and endangered animals, are filed fairly consistently in federal court according to Docket Alarm analytics. The data shows that filings under the Environmental Matters PACER Nature of Suit tag occurred an average of 1.3 times each day during the last two years.  These environmental lawsuits are filed fairly consistently although there are some spikes, and the lawsuits tend to lag in November of both years.  There was a dip in litigation between March and June 2020, likely connected to the COVID-19 pandemic-related shutdowns. Filings picked up by the end of summer with 52 filings in August. Overall, there have been 954 federal lawsuits filed under the Environmental Matters case tag since the beginning of 2019. 

No Summary Judgment in Pharma Org s Challenge to State Law

Health your username January 6, 2021 On Monday, in the California Eastern District, the Pharmaceutical Research and Manufacturers of America (PRMA) was denied a motion for summary judgment for its requested injunction to block a new California state law requiring certain public disclosures for drug manufacturers when prescription drug costs increase.  The relevant law required the manufacturer to provide to all purchasers a disclaimer no later than 60 days prior to a price increase of more than 16% for a prescription drug created by the manufacturer. The disclaimer must explain why the price increase was warranted, including what benefits the changes provided and why the specific price increase was tailored to fit said benefit. 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.